Preliminary Agenda

Central nervous system disorders (CNS) make up more than 600 conditions that affect over 2 billion people worldwide with an estimated economic burden of more than $2 trillion in the US and EU alone. Due to this unmet medical need and financial burden, the neurotechnology sector has seen important increases in investment over the last decade. Now in its fourth year, the European Neurotech Investing and Partnering Conference is the premier partnering and investing conference for the neurotechnology industry, spanning pharmaceuticals, medical devices, software, and diagnostics for the brain and nervous system. This event will bring together C-level executives, investors, and entrepreneurs to address challenges in investing, funding, partnering, and development of new treatments and diagnostics for the brain and nervous system. Overall, this event will provide delegates with a forum to learn, network, and shape the future of their organization and the industry.

WELCOME AND STATE OF THE INDUSTRY KEYNOTE
Welcome Remarks

Alison Fenney, Executive Director, Neurotechnology Industry Organization

Keynote Presentation
John Donoghue, Ph.D., Founding Director, Wyss Center

PANEL DISCUSSION: INVESTING IN NEUROTECH
A diverse panel of private, public and strategic investors will discuss what it takes to get a neurotech company funded. The benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology will be addressed. Delegates will learn more about today's deal terms and valuations as well as exit strategies. Finally, the neurotech industry will be evaluated in comparison with other industries.

Panelists:
Daniel Bertholet, Senior Investment Director, Endeavour Vision
Jasper Bos, Ph.D., Vice President, Head, Healthcare Fund, Merck Ventures

TREATMENT FOR ALZHEIMER’S AND COGNITIVE DISORDERS
Alzheimer’s disease and related dementias affect over 46 million people worldwide, with an estimated cost of $818 billion. Ongoing efforts to develop disease modifying therapies have been plagued with failures. This session will address new avenues being pursued to address the growing global need, novel diagnostics for early detection, and non-pharmacological options in development.

Speakers:
Martin Tolar, M.D., Ph.D., Founder, President & CEO, Alzheon, Inc.
Charles Stacey, M.D., President and CEO, Accera
Dirk Beher, Ph.D., CEO, Asceneuron SA
Carlos Buesa, CEO, Oryzon

FRONTIERS IN NEUROTECHNOLOGY
This session includes companies on the cutting edge of neuroscience. Novel neurostimulation devices for a variety of indications, software solutions for neuropsychiatric markets, and new neurodiagnostic tools are on the brink of success. Companies in this session will showcase their innovative next-generation products and how they are addressing unmet needs in neurotech.

Moderator: John B. Reppas, M.D., Ph.D., Director of Public Policy, Neurotechnology Industry Organization
Speakers:
Ann Bunnenberg, Ph.D., JD, COO and President, Electrical Geodesics, Inc.
Beth Rosellini, Vice President, Clinical Affairs, Nexeon Medsystems
Martin Jamieson, CEO, Nexstim
Frederic Sottelini, CEO, CarThera

PANEL DISCUSSION: INTERNAL & EXTERNAL RESEARCH AND DEVELOPMENT

Big pharma, medtech, and biotech companies collaborate with smaller companies and academic institutions on a variety of projects. This panel discussion will address opportunities for research and development collaborations with academic groups, research institutes, and platform companies. Delegates will learn how to spot opportunities, current areas of interest, and how to focus internal and external resources.

Panelists:
Pierandrea Muglia, Vice President, Neuroscience Discovery, UCB Pharma
Jeff Erb, Senior Director, Strategy, Business Development and Alliance Management, Medtronic
Additional Panelists to be Announced

DEVELOPMENTS ON THE HORIZON FOR PAIN AND EPILEPSY
Ongoing research is revealing new pharmaceutical and device options to treat pain and epilepsy. Novel therapeutic modalities aim to decrease side effects and improve efficacy in treatment-resistant populations for epilepsy and neuropathic pain. This session will showcase novel devices in this space as well as strategies for mitigating side effects.

Speakers to be Announced

EMERGING COMPANY SHOWCASE
This showcase allows neurotechnology companies to pitch their drug, device, diagnostic, or software to an audience of investors, CEOs, and executives in the field. Companies presenting in this session are addressing unmet medical needs, were founded no earlier than 2012, and are actively seeking funding.

Now Accepting Submissions 

BENCH TO BEDSIDE: PROFILING TO WYSS CENTER
This session will feature discussions around the funding and de-risking of early neurotech concepts, offer advice on how to attract investors, and give tips on how to avoid common pitfalls on the journey of a new concept from lab bench to the clinic.

Moderator: Tracy Laabs, Ph.D., Assistant Director, Wyss Center
Speakers:
Claude Clément, CTO, Wyss Center
Daniel O’Connell, MBA, Founding member & Managing Partner, NeuroVentures; President and Chief Executive Officer, Acumen Pharmaceuticals, Inc.
Hunter Peckham, Ph.D., Associate Director, Technology Transfer, Cleveland FES Center; Distinguished University Professor, Donnell Institute Professor of Biomedical Engineering, and Professor of Orthopaedics; Executive Director, Institute for Functional Restoration, School of Medicine, Case Western Reserve University; Senior Research Career Scientist, and Biomedical Engineer, Louis Stokes Cleveland VA Medical Center
Claudio Pollo, M.D., Head, Functional Neurosurgery, University Hospital Berne, Switzerland

PANEL DISCUSSION: PARTNERING AND LICENSING IN NEUROTECH
Neurology is projected to be medtech’s fastest-growing segment in the next five years. Pharma companies are adapting to the current environment with targeted deal-making. This panel will address current trends in strategic alliances and inlicensing, priority indications and requirements for licensing deals, and companies active in deal-making.

Panelists:
Maciek Drozdz, Principal, Venture Investments, J&J Development Corporation
Charlie Bailey, Ph.D., Global Head, Neuroscience, Business Development & Licensing, Novartis
Additional Panelists to be Announced

STRATEGIES IN CNS DRUG AND DEVICE DEVELOPMENT (Sponsorship opportunities available)
Intelligent trial design, fundraising, business development and product life cycle development strategy is critical to the success of any neurotech venture. An insider panel will discuss specific tactics for improving drug and device development to navigate a path to approval and reimbursement.

Moderator: Carla M. Lema Tome, MBA, Ph.D., INC Research

NEXT-GENERATION PSYCHIATRY
Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a substantial portion of the neurotech market. This session will focus on the most promising next-generation treatments as well as devices and diagnostics to change the treatment landscape.

Speakers:
Adrian Attard Trevisan, Ph.D., Co-Founder/Director, Umana Medical Technologies
Additional Speakers to be Announced

THERAPEUTIC GENE DELIVERY IN NEUROSCIENCE
Next-generation strategies for crossing the blood brain barrier including vector transport, gene therapy, encapsulated cells and neurodevices, which will be featured and discussed in this session. Case studies in glioblastoma, Alzheimer's, Parkinson's and other areas will highlight the potential for new classes of treatments to be developed.

Speakers:
Jesús Martin-Garcia, Chairman and CEO, GeNeuro
Additional Speakers to be Announced

PARKINSON’S AND OTHER MOVEMENT DISORDERS
Current treatments for movement disorders can improve functioning but suffer from side effects and “off” periods especially as the disease progresses. In this session, speakers will share the latest advances in movement disorders including how to address side effects, disease modifying treatments, and the role of diagnostics in improving outcomes.

Speakers:
Oliver Siegel, CEO, AFFiRis AG
Atsushi Hashimoto, Director, Business Development, Mitsubishi Tanabe Holdings America, Inc.
Additional Speakers to be Announced

TARGETING ORPHAN DISEASES
Orphan disorders are an appealing area of investment due to benefits with regulatory agencies, ready access to patients, and premium pricing. This session will feature companies developing treatments for ALS, lysosomal storage disorders, Huntington's, and more. They will outline strategies for breaking into a smaller market as well as how R&D approaches differ from other indications.

Speaker:
Xavier Paoli, Chief Commercial Officer; VP R&D Operations, Pharnext
Additional Speakers to be Announced

Demographics

NIO

 

 

View All Sponsors

 

 

Premier Sponsor

FloreyLogo

 

 

View_Media

FreeMindLogo


Neurotech